Article ID Journal Published Year Pages File Type
10148669 Clinical Immunology 2018 22 Pages PDF
Abstract
TNFα-antagonists are safe and might be associated with a decreased risk of relapse at 9 months compared to conventional immunosuppressants in BD patients with major vessels disease.
Related Topics
Life Sciences Immunology and Microbiology Immunology
Authors
, , , , , , , , , , , , , , , , , , ,